Hemogenyx Announces Submission of Complete Response to Clinical Hold
LONDON, UK / ACCESSWIRE / September 28, 2023 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the Standard Listed biopharmaceutical group developing therapies designed to transform blood disease treatment, announces its unaudited interim results for the six-month period ended 30 June 2023.
Hemogenyx Pharmaceuticals now knows what it will take to lift the clinical hold on its CAR-T cell therapy candidate. In its full review letter, the FDA cited a manufacturing issue as the cause of the hold, leading the biotech to identify the source of the problem and develop a solution.